JP2012523431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523431A5 JP2012523431A5 JP2012504881A JP2012504881A JP2012523431A5 JP 2012523431 A5 JP2012523431 A5 JP 2012523431A5 JP 2012504881 A JP2012504881 A JP 2012504881A JP 2012504881 A JP2012504881 A JP 2012504881A JP 2012523431 A5 JP2012523431 A5 JP 2012523431A5
- Authority
- JP
- Japan
- Prior art keywords
- lysosomal storage
- diol
- storage disorder
- prodrug
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810909P | 2009-04-09 | 2009-04-09 | |
| US61/168,109 | 2009-04-09 | ||
| PCT/US2010/030472 WO2010118283A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating lysosomal storage disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523431A JP2012523431A (ja) | 2012-10-04 |
| JP2012523431A5 true JP2012523431A5 (enExample) | 2013-05-16 |
| JP5645918B2 JP5645918B2 (ja) | 2014-12-24 |
Family
ID=42934559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504881A Expired - Fee Related JP5645918B2 (ja) | 2009-04-09 | 2010-04-09 | リソソーム蓄積障害の予防および／または治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8940766B2 (enExample) |
| EP (1) | EP2416656B1 (enExample) |
| JP (1) | JP5645918B2 (enExample) |
| CN (1) | CN102625661B (enExample) |
| AU (1) | AU2010233188B2 (enExample) |
| BR (1) | BRPI1010517A2 (enExample) |
| CA (1) | CA2758271C (enExample) |
| ES (1) | ES2564093T3 (enExample) |
| IL (1) | IL215583A (enExample) |
| NZ (1) | NZ595629A (enExample) |
| WO (1) | WO2010118283A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| WO2010118282A1 (en) * | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| CN102647905B (zh) | 2009-10-19 | 2015-09-09 | 阿米库斯治疗学公司 | 用于预防和/或治疗溶酶体贮积失调的新颖组合物 |
| ES2814178T3 (es) | 2009-10-19 | 2021-03-26 | Amicus Therapeutics Inc | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central |
| KR20230066482A (ko) | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| MX2016010365A (es) * | 2014-02-12 | 2016-11-30 | Amicus Therapeutics Inc | Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic. |
| KR20250004926A (ko) | 2014-09-30 | 2025-01-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제 |
| KR102510941B1 (ko) | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| KR102790256B1 (ko) | 2016-03-30 | 2025-04-04 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 고 m6p 재조합 단백질의 선택 방법 |
| WO2017173060A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| DK3624831T5 (da) | 2017-05-15 | 2024-09-02 | Amicus Therapeutics Inc | Rekombinant human sur alfa-glucosidase |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| NZ257212A (en) | 1992-09-29 | 1996-11-26 | Inhale Therapeutic Syst | Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone |
| JP4128615B2 (ja) | 1994-03-09 | 2008-07-30 | ノボ ノルディスク アクティーゼルスカブ | ピペリジン及びピロリジン |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU2002306848A1 (en) * | 2001-03-23 | 2002-10-08 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| AU2003273762A1 (en) | 2002-10-28 | 2004-05-13 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| AU2004289327A1 (en) * | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease |
| AU2007260812B2 (en) * | 2006-06-23 | 2012-08-16 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase |
| US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2010048532A1 (en) | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| WO2010118282A1 (en) * | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
-
2010
- 2010-04-09 JP JP2012504881A patent/JP5645918B2/ja not_active Expired - Fee Related
- 2010-04-09 NZ NZ595629A patent/NZ595629A/xx not_active IP Right Cessation
- 2010-04-09 CN CN201080023544.XA patent/CN102625661B/zh not_active Expired - Fee Related
- 2010-04-09 CA CA2758271A patent/CA2758271C/en not_active Expired - Fee Related
- 2010-04-09 US US12/757,160 patent/US8940766B2/en active Active
- 2010-04-09 ES ES10762469.4T patent/ES2564093T3/es active Active
- 2010-04-09 WO PCT/US2010/030472 patent/WO2010118283A1/en not_active Ceased
- 2010-04-09 EP EP10762469.4A patent/EP2416656B1/en not_active Not-in-force
- 2010-04-09 AU AU2010233188A patent/AU2010233188B2/en not_active Ceased
- 2010-04-09 BR BRPI1010517A patent/BRPI1010517A2/pt not_active Application Discontinuation
-
2011
- 2011-10-06 IL IL215583A patent/IL215583A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523431A5 (enExample) | ||
| NZ595629A (en) | Methods for preventing and/or treating lysosomal storage disorders | |
| Coutinho et al. | Less is more: substrate reduction therapy for lysosomal storage disorders | |
| JP2012523430A5 (enExample) | ||
| HK1209318A1 (en) | Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof | |
| WO2012012300A3 (en) | Treatment of the adverse side-effects associated with administration of an anti-hyaluronan agent | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| BRPI1011593A2 (pt) | "combinação farmacêutica, composição farmaceuticamente aceitavél, e, método para tratar um distúrbio metabólico, para tratar doença pulmonar obstrutiva crônica, e para tratar ou prevenir um ou mais distúrbios metabólicos." | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| BR112013004443A8 (pt) | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas | |
| WO2011127241A3 (en) | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| FR2934995B1 (fr) | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique | |
| MY151230A (en) | Novel method | |
| WO2010045522A3 (en) | Combination therapies for the treatment of obesity | |
| WO2009019295A3 (en) | Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases | |
| De Luca et al. | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. | |
| EP2945626A1 (en) | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy | |
| WO2010045416A3 (en) | Combination therapies for the treatment of obesity | |
| Salas et al. | Opposing actions of chronic stress and chronic nicotine on striatal function in mice | |
| Wilcock et al. | Drug highlight: Pilocarpine. | |
| Conrad et al. | Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection | |
| FR2934996B1 (fr) | Composes polysubstitues d'azetidines, leur preparation et leur application en therapeutique | |
| WO2008126085A3 (en) | Method for treating bone marrow disorders |